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Abstract
This study described a broad clinical characterization of classical homocystinuria (HCU) in Brazil. This was a cross-sectional,
observational study including clinical and biochemical data from 72 patients (60 families) from Brazil (South, n¼ 13; Southeast, n¼
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37; Northeast, n ¼ 8; North, n ¼ 1; and Midwest, n ¼ 1). Parental consanguinity was reported in 42% of families. Ocular
manifestations were the earliest detected symptom (53% of cases), the main reason for diagnostic suspicion (63% of cases), and
the most prevalent manifestation at diagnosis (67% of cases). Pyridoxine responsiveness was observed in 14% of patients. Only
22% of nonresponsive patients on treatment had total homocysteine levels <100 mmol/L. Most commonly used treatment
strategies were pyridoxine (93% of patients), folic acid (90%), betaine (74%), vitamin B12 (27%), and low-methionine diet þ
metabolic formula (17%). Most patients diagnosed with HCU in Brazil are late diagnosed, express a severe phenotype, and poor
metabolic control. Milder forms of HCU are likely underrepresented due to underdiagnosis.
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Introduction
Classical homocystinuria (HCU; OMIM 236200) is an inborn
error of methionine metabolism caused by deficient activity of
cystathionine b-synthase (CbS; EC 4.2.1.22). Cystathionine
b-synthase deficiency leads to massive accumulation of
homocysteine and methionine and low levels of cysteine.1,2
Homocystinuria was first described in 19623; since then, many
advances in treatment and early diagnosis, including newborn
screening, have improved prognosis dramatically.4–6 However,
diagnosis and management of HCU is still a major challenge in
developing countries, where newborn screening is unavailable
and access to health-care services is often poor and unequal.7
From a clinical standpoint, the classic signs of HCU are
lens dislocation, thromboembolism, mental retardation, psy-
chiatric disorders, osteoporosis, and marfanoid features.8
Established treatment strategies include supplementation of
pyridoxine (CbS cofactor), folic/folinic acid, betaine, and a
methionine-restricted diet supplemented with an essential
amino acids admixture free of methionine.9 Novel therapies
with chaperones and enzyme replacement are currently under
development.10–12 Usually, patients who respond to pyridox-
ine supplementation exhibit a milder phenotype and have a
better prognosis.8
The worldwide prevalence of HCU is estimated to be
1:100 000.13 However, several mild and late presentation phe-
notypes have been described,14–16 raising the issue of whether
HCU is largely underdiagnosed. Newborn screening for HCU is
performed in some countries with high incidence of the disease,
such as Ireland and Qatar.5,17 Usually, newborn screening is
performed by the determination of methionine on filter paper.
However, this method has a large percentage of false negatives
(up to 50%), since pyridoxine-responsive HCU may not present
with hypermethioninemia in the first days of life.18,19 In Brazil,
the prevalence of HCU is unknown, and the disease is not
included in the National Neonatal Screening Program.
Brazil is a very large country with over 200 million inhabi-
tants, and the country is characterized by intense admix-
ture.20,21 The country also has one of the world’s largest
publicly funded health-care systems, the Unified Health
System (Sistema Único de Saúde), which was established to
provide equitable and comprehensive care to all users. How-
ever, betaine and the methionine-free amino acid formulation
are not available through Unified Health System, and few cen-
ters across the country offer biochemical testing for diagnosis
and management of this condition. Furthermore, several factors
make diagnosis and management of HCU within the Brazilian
health system a major challenge; hence, a substantial number of
patients with this treatable condition are believed to remain
undiagnosed and thus untreated. Within this context, the pres-
ent study sought to establish a broad clinical characterization of
HCU in Brazil through a survey on diagnosis and management
of a representative patient population that is being followed at
several centers nationwide.
Materials and Methods
The present study was approved by the local research ethics
committee. Collection procedures for the study were conducted
only after participants or their caregivers had agreed to take part
in the investigation and provided written informed consent.
Patients
The study sample comprised 72 Brazilian patients with a diag-
nosis of HCU, from 60 different families. Diagnosis was in
general made on clinical symptoms followed by clear eleva-
tions in homocysteine and methionine. Mutation analyses was
performed in 35 of the 72 patients.22 Families from all 5
regions of Brazil were represented: South (n ¼ 13), Southeast
(n ¼ 37), Northeast (n ¼ 8), North (n ¼ 1), and Midwest (n ¼
1). Patients were recruited through contact with physicians
involved in care and/or research activities at medical genetics
centers across the country. A structured questionnaire contain-
ing queries regarding diagnosis, consanguinity, treatment stra-
tegies, metabolic control, and current health condition of
patients with HCU was sent to 15 medical centers that had
agreed to participate in the study. Clinical data regarding diag-
nosis were available only for 28 patients.
All 72 patients had delayed diagnoses: 62 patients had been
diagnosed after clinical suspicion and biochemical findings
consistent with HCU (hyperhomocysteinemia and hyper-
methioninemia), and the remaining 10 had been diagnosed on
family screening. Each of the participating centers used a dif-
ferent protocol for determination of pyridoxine responsiveness.
For the purposes of this study, patients were classified as
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responsive if they achieved homocysteine levels <50 mmol/L
on pyridoxine alone or pyridoxine þ folic acid (regardless of
the number of weeks since testing). All other patients were
classified as nonresponsive to pyridoxine.
Target total homocysteine levels on treatment were set
according HCU guidelines,9 which were <50 mmol/L for
pyridoxine-responsive patients and <100 mmol/L for nonre-
sponsive patients. Treatment adherence was determined by the
subjective impressions of the care team at each medical center.
Statistical Analysis
Statistical analysis was performed using SPSS for Windows,
version 18.0 (SPSS Inc, Chicago, Illinois). Asymmetrically
distributed variables were expressed as the median (range). The
Mann-Whitney U test (continuous variables) or w2 test (cate-
gorical variables) was used to assess between-group differ-
ences. Values of P < .05 were considered significant.
Results
Of the 72 patients included, 55% were male. Two patients were
already deceased at the time of inclusion in the study (presum-
ably due to thromboembolic events). The patients belonged to
60 families; parental consanguinity was reported in 25 (42%)
families. Median age at assessment was 19 years. The youngest
patient was aged 5, and the oldest was 45. Regarding pyridox-
ine responsiveness, 61 (85%) patients were classified as non-
responsive and 10 (13.8%) as responsive. In 1 patient,
pyridoxine responsiveness was not reported/determined.
Journey to Diagnosis
The very first symptom noticed by families and/or physicians
was visual impairment (mainly due to ectopia lentis) in 53% of
the cases, followed by developmental delay (22% of cases),
seizures (11% of cases), and isolated thromboembolic episodes
(9.5% of cases). Table 1 reports clinical features at diagnosis
for the sample as a whole and stratified by pyridoxine
responsiveness.
The median time elapsed between symptom onset and diag-
nosis was 5 years (maximum, 34 years). One-third of the
patients had 3 or more systems already affected at the time
of diagnosis. The main clinical findings leading to investiga-
tion of HCU are represented in Figure 1. Eye disease, the most
prevalent symptom at diagnosis (67% of cases), accounted for
63% of referrals for HCU investigation.
Management
Current clinical and biochemical data were available for 44
patients, of whom 7 were responsive and 37 were nonrespon-
sive to pyridoxine. The median length of follow-up was 6 years
(range, 0-27 years). Table 2 describes clinical manifestations
and biochemical control in this group of patients. Ocular man-
ifestations were more prevalent among pyridoxine-
nonresponsive patients (71% vs 97%, P ¼ .01). Ectopia lentis
was the most common complication in our sample, affecting
91% of patients at the time of study inclusion.
Pyridoxine-responsive patients had significantly lower total
homocysteine levels at study inclusion (P < .001). Only 22% of
nonresponsive patients achieved target total homocysteine lev-
els (<100 mmol/L) on treatment, while all responsive patients
(n ¼ 7) had total homocysteine <50 mmol/L. Treatment adher-
ence was reported as appropriate in 44% of patients.
Regarding treatment strategies, 93% of patients were on
pyridoxine supplementation, 90% on folic acid, 74% on
betaine, 27% on vitamin B12, and only 17% on a low-
methionine diet þ metabolic formula.
Discussion
The present report provides the largest clinical profile of
patients with HCU ever studied in Brazil to date. Clinical
data of 72 patients (60 unrelated) from 15 medical genetics
centers across Brazil were analyzed. Most families lived in
the South and Southeast regions of the country. These
regions are home to 57% of the country’s population
(http://www.ibge.gov.br/) and, compared to other regions
of Brazil, have higher rates of access to health-care services
and procedures. The fact that patients from other regions,
particularly the North (n ¼ 1) and Midwest (n ¼ 1), were
underrepresented suggests high rates of HCU underdiagno-
sis and/or limited access to care in these regions.7
A high proportion of pyridoxine-nonresponsive patients
with HCU was found in our study (85%). Nonresponsive
patients usually present a more severe phenotype, have more
complications, and younger ages .6,8,23 In our study, this pro-
portion exceeded rates described worldwide of approximately
50%.8 In countries where the proportion of nonresponsive
patients is disproportionately high, such as Qatar and Ireland,










Current age, years 19 (5-45) 23 (14-35) 18 (5-45) .120
Age at first symptom
onset, years
5 (0-20) 2 (0.2-15) 5 (0.7-20) .316
Age at diagnosis, years 10 (1-39) 11 (4-34) 9 (1-39) .545
Systems affected at
diagnosis, %
Ocular 72 50 75 .100
CNS 60 70 59 .497
Skeletal 60 40 54 .401
Vascular 15 20 14 .625
Abbreviation: CNS, central nervous system.
aN ¼ 72, data expressed as the median (range) or percentage. In 1 patient,
pyridoxine responsiveness could not be determined, data from this patient
were used alone in the whole-group analysis.
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specific genotypes are highly prevalent and account for these
discrepancies .24,25 In a previous study of our group, we
explored in more depth the genotype of 35 patients with HCU
who are also included in the current study.22
Our results show there is no single molecular basis for the
high prevalence of HCU nonresponsive phenotypes in Brazil.
In fact, the most prevalent mutation in that study (p.Ile278Thr)
is a pyridoxine-responsive mutation. Another genetic study of
14 Brazilian patients with HCU showed similar results.26 These
findings rather suggest underdiagnosis of pyridoxine-
responsive patients in Brazil who express milder phenotypes
with fewer symptoms and later onset of clinical presentation.6,8
In our study, no significant differences in age at symptom onset
or age at diagnosis were found between pyridoxine-responsive
and nonresponsive patients; however, we believe our analysis
was underpowered because of the low number of pyridoxine-
responsive patients (n ¼ 10 vs n ¼ 61, respectively).
The high prevalence of ocular manifestations at diagnosis
and their predominant contribution to diagnostic suspicion
reinforce the importance of eye disease in HCU. Ectopia len-
tis is usually the earliest manifestation of HCU, occurring in
half of all untreated patients by age 10 years and in over 90%
by age 24 years.8 No significant difference in the prevalence
of ocular manifestations at diagnosis was found between
responsive and nonresponsive patients (75% vs 50%, P ¼
.10), although the lack of significance could also be explained
by the small sample size. However, this finding is consistent
with previous reports in the literature.8
Skeletal and neurologic manifestations were also highly
prevalent at diagnosis, affecting more than half of patients of
our cohort. The lower prevalence of vascular events at diag-
nosis is consistent with the natural history of HCU, in which
such manifestations usually occur in general at a later age.8
However, vascular disease may have been underrepresented
due to the high lethality of thromboembolic events. The rela-
tive large time gap between symptom onset to diagnosis (med-
ian, 5 years) and the presence of multiple clinical
manifestations attest to the difficulty in establishing a defini-
tive diagnosis in these patients.
The main strategies and goals of HCU treatment have been
recently established in the first guidelines for the diagnosis and
management of CbS deficiency.9 Early diagnosis and early
treatment are the key to prevent clinical manifestations and
improve prognosis.4,18In the present study, current clinical and
biochemical data were obtained from 44 patients in treatment.
There was a clear difference in metabolic control between the
groups: Responsive patients had low and even near-normal
homocysteine and methionine levels, whereas most nonrespon-
sive patients had persistently high homocysteine levels
(>100 mmol/L) despite multiple treatment strategies. This dif-
ficulty in achieving metabolic control in pyridoxine-
nonresponsive patients has been reported elsewhere.18,27,28
Figure 1. Main reasons for clinical suspicion of classical homocystinuria in our sample (N ¼ 72). *Including marfanoid habitus,
**Other than ectopia lentis.
Table 2. Classical Homocystinuria in Brazil: Clinical and Biochemical









Current age, years 16 19 (14-35) 16 (5-37) .182
Homocysteine, mmol/L 168 19 (14-34) 212 (9-455) <.001
Methionine, mmol/L 131 27 (23-650) 218 (6-881) .065
Clinical manifestations, %
Ocular 93 71 97 .013
CNS 70 86 68 .318
Skeletal 61 57 62 .803
Vascular 25 14 27 .475
Abbreviation: CNS, central nervous system.
an¼ 44, data expressed as the median (range) or percentage; reference ranges:
homocysteine, 5-15 mmol/L; methionine, 5-30 mmol/L.
4 Journal of Inborn Errors of Metabolism & Screening
The high rate of betaine supplementation and compara-
tively low use of methionine-restricted diet in the nonrespon-
sive patients may be attributed to several factors: (1)
difficulties in obtaining the metabolic formula, which is
expensive and not provided by the Unified Health System in
Brazil;29 (2) low adherence to dietary methionine restriction,
particularly in patients with a late diagnosis; and (3) limited
training of health-care professionals in dietary prescription. In
a European survey of 181 patients with pyridoxine-
nonresponsive HCU, 66% were on dietary treatment, that is,
twice as many as in the present study.30 Homocystinuria
guidelines clearly state that betaine should not be considered
a first-line treatment for HCU-nonresponsive patients but
used as adjunct treatment in those who cannot achieve target
levels of homocysteine by other means.9 While dietary ther-
apy dramatically reduces methionine and homocysteine and
normalizes cysteine, betaine supplementation reduces homo-
cysteine but increases methionine levels.31,32 In animal mod-
els, betaine is less effective at preventing clinical
manifestations,33 and its efficacy declines over time.34 In
humans, there are no studies of the long-term efficacy of
betaine supplementation alone in HCU.
In conclusion, this study provides the first broad clinical
characterization of HCU in Brazil. All patients described here
were late diagnosed, and most expressed a severe phenotype
associated with nonresponsiveness to pyridoxine, early and
multisystem clinical manifestations, and poor metabolic con-
trol. Limitations of this study include the underrepresented
number of patients responsive to pyridoxine, and the number
of patients coming from some regions of the country. We
believe that our findings will contribute to the development
of protocols and guidelines to improve diagnosis and manage-
ment of HCU in Brazil.
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